Immune-tumor interaction dictates spatially directed evolution of esophageal squamous cell carcinoma

Yong Zhou,Shanlan Mo,Heyang Cui,Ruifang Sun,Weimin Zhang,Xiaofei Zhuang,Enwei Xu,Hongyi Li,Yikun Cheng,Yongsheng Meng,Meilin Liu,Ting Yan,Huijuan Liu,Ling Zhang,Bin Yang,Yanfeng Xi,Shubin Wang,Xiaolong Cheng,ShuaiCheng Li,Zhihua Liu,Qimin Zhan,Zheng Hu,Yongping Cui
DOI: https://doi.org/10.1093/nsr/nwae150
IF: 20.6
2024-04-23
National Science Review
Abstract:Abstract Esophageal squamous cell carcinoma (ESCC) is a poor-prognostic cancer type with extensive intra- and inter-patient heterogeneity in both genomic variations and tumor microenvironment (TME). However, the patterns and drivers of spatial genomic and microenvironmental heterogeneity of ESCC remain largely unknown. Here, we generated a spatial multi-omic atlas by whole-exome, transcriptome, and methylome sequencing of 507 tumor samples from 103 patients. We identified a novel tumor suppressor PREX2, accounting for 22% ESCCs with frequent somatic mutations or hyper-methylation, which promoted migration and invasion of ESCC cells in vitro. Analysis of the tumor microenvironment and quantification of subclonal expansion indicated that ESCCs undergo spatially directed evolution, where subclones mostly originated from the tumor center but had a biased clonal expansion to the upper direction of the esophagus. Interestingly, we found upper regions of ESCCs often underwent stronger immunoediting with increased selective fitness, suggesting more stringent immune selection. In addition, distinct TMEs were associated with variable genomic and clinical outcomes. Of which, hot TME was associated with high immune evasion and subclonal heterogeneity. We also found that immunoediting, instead of CD8+ T cell abundance, acts as an independent prognostic factor of ESCCs. Importantly, we found significant heterogeneity in previously considered potential therapeutic targets, as well as BRCAness characteristics in a subset of patients, emphasizing the importance of focusing on heterogeneity in ESCC targeted therapy. Collectively, these findings provide novel insights into the mechanisms of the spatial evolution of ESCC and inform precision therapeutic strategies.
multidisciplinary sciences
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the patterns of spatial genome and micro - environment heterogeneity in esophageal squamous cell carcinoma (ESCC) and their driving factors. Specifically, through multi - regional sampling and multi - omics analysis methods, the researchers sequenced the whole exome, transcriptome and methylome of 507 tumor samples from 103 patients, aiming at: 1. **Revealing the spatial genome and micro - environment heterogeneity of ESCC**: Through a high - resolution spatial multi - omics atlas, the researchers hope to identify the genomic variations and micro - environment characteristics of ESCC at different spatial locations, and how these characteristics affect tumor evolution and clinical prognosis. 2. **Discovering new tumor - suppressor genes**: A new tumor - suppressor gene PREX2 was identified in the study. This gene has frequent somatic mutations or hypermethylation in 22% of ESCC patients, and has been confirmed to be able to promote the migration and invasion of ESCC cells in vitro experiments. 3. **Proposing a spatially - directed evolution model of ESCC**: By analyzing the tumor micro - environment and sub - clone expansion, the researchers found that the sub - clones of ESCC mainly originate from the tumor center, but tend to expand towards the upper part of the esophagus. This finding indicates that the immune - editing ability plays an important role in the spatial evolution of ESCC. 4. **Evaluating the relationship between the immune micro - environment and genomic variations**: The researchers also explored the associations between different tumor micro - environments (such as "hot" and "cold" tumors) and specific genomic variations, and found that certain gene mutations (such as CDKN2A, NOTCH1 and EPHA2) are enriched in immune "cold" tumors, while other gene mutations (such as PIK3CA, ERBB2 and CCND1) are enriched in immune "hot" tumors. 5. **Evaluating the role of immune - editing as an independent prognostic factor**: The study found that immune - editing ability, rather than CD8+ T - cell abundance, can be used as an independent prognostic factor for ESCC. In addition, ESCC patients with BRCAness features showed better prognoses in three independent data cohorts, suggesting that these patients may benefit from platinum - based chemotherapy and PARP inhibitor treatment. In conclusion, through multi - omics analysis methods, this paper systematically explored the spatial genome and micro - environment heterogeneity of ESCC, providing new insights for understanding the evolution mechanism of ESCC and developing precise treatment strategies.